Seventh Framework Programme and European Commission logos

Advancing the development of life-saving drugs for cardiovascular diseases

ImaBiotech SAS


ImaBiotech will optimize sample preparation for clinical tissue in WP3 (Target validation – clinical tissue) and develop new methodology to evaluate potential small molecular weight biomarker. In fact, molecular profiling of metabolites will be performed directly on tissue sections with high specificity and sensitivity by utilizing matrix-assisted laser desorption ionization mass spectrometry (MALDI MS). Correlation between specific distribution of molecules and tissue area will be achieved in order to highlight potential biomarker of the pathology. The identification and validation of candidate biomarkers found in tissue sections require establishing a global approach consisting in tissue selection, sample preparation, analysis parameters optimization, structural elucidation, statistical analysis and validation step.

ImaBiotech is a spin off from the CNRS/University of Lille, dedicated to the development of mass spectrometry tools for drug and biomarker developments. ImaBiotech is a Contract Research Organization (CRO) that offers innovative services to accelerate molecular identification, including quantification via cutting-edge mass spectrometry and MS imaging techniques for the pharmaceutical and medical diagnostics fields. ImaBiotech developed a huge mass spectrometry platform and expertise for the biomarker discovery (mass spectrometry) and a Mass Spectrometry Immune-Assay technology for high throughput biomarkers quantitation (patents, publications). ImaBiotech collaborates in FP7 program, HiPad, for the development of CHIP-SPR-Mass spectrometry platform for high throughput detection of protein interaction and is implicated in French research program (ANR Piribio MASDA-EYE) for the biomarker discovery linked to drug toxicity in ophthalmology. ImaBiotech has many partners with top 10 pharmaceutical companies for the development of mass spectrometry tools dedicated to metabolites research and also collaborates with Biotech and public lab in order to develop new tools in Biomarker discovery and diagnostic market (In vitro Diagnostic, IVD).

ImaBiotech is specialized in molecular imaging using mass spectrometry (MS). We have developed a huge knowledge of sample preparation and analysis thanks to many projects or collaborations on different biological problematic or therapeutics areas. Moreover, we have generated a unique proprietary database dedicated to MSI of endogenous metabolites of tissue which permits the high throughput identification and localization of small molecular weight compounds directly on tissue section. Furthermore, ImaBiotech has recently acquired the most performing analytic tool available in the market of mass spectrometry, the FTICR mass spectrometer. It offers high mass measurement accuracy (below ppm level) and ultra-high resolution (1 000 000) which permits univocal characterization of molecular ions on mass spectra. The combination of these two factors allows us to perform the identification and validation of new biomarkers for cardiovascular disease.